Login
PRECISION BIOSCIENCES INC logo

PRECISION BIOSCIENCES INC

precisionbiosciences.com

What Do They Do?

Develops ARCUS-based gene-editing therapies for genetic and infectious diseases, including chronic hepatitis B and Duchenne muscular dystrophy.

How Do They Make Money?

Most revenue comes from collaboration and license agreements. Partners pay upfront and option fees, fund research and development, and may make milestone payments; the company may also earn royalties when licensed products are sold.

FY2025 revenue

Who Are Their Customers?

Biotechnology and pharmaceutical companies partner with Precision to develop, manufacture, or commercialize product candidates and license its technology.

Do Revenues Turn Into Profits?

No. It lost $45.7M in FY2025.

Operating income, FY2025
−152% of revenue
▼ −99% (Loss) vs FY2024 (−$26.2M, −38%)
Net income, FY2025
−133% of revenue
▼ Turned to a loss vs FY2024 ($7.2M, 10%)
Free cash flow, FY2025
−192% of revenue
▼ −12% (Loss) vs FY2024 (−$58.7M, −85%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −100%
vs $13K in Q3 FY2025
Net income
▲ +65% (Loss)
vs −$21.8M in Q3 FY2025
  • Nov 5, 2026 Precision priced a $125 million stock offering The company plans to use net proceeds to fund research and development of PBGENE-HBV and PBGENE-DMD, and for working capital and general purposes.
  • Nov 5, 2026 PBGENE-HBV advances to Phase 2 The company reported Phase 1 results and plans to begin Phase 2 dosing in the first quarter of 2027.

Shrinking. Revenue fell 70% in 4 years, from $115.5M in FY2021 to $34.3M in FY2025, about 26% a year.

Focus on in vivo therapies The latest report centers on in vivo therapies for genetic and infectious diseases. The older report also described development of ex vivo CAR T immunotherapies for cancer and a strategy to build integrated research, development, manufacturing, and commercial capabilities.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support